Lupin Pharmaceuticals Inc. is recalling 6,294 bottles of Memantine Hydrochloride Extended Release Capsules (21 mg), which is used to treat symptoms of Alzheimer's disease. The recall was initiated because the medication failed a dissolution test during a six-month stability study, meaning the drug may not dissolve at the correct rate in the body. These 30-count bottles were distributed nationwide across the United States.
If the medication fails to dissolve as specified, the drug may not be absorbed properly by the body, which can lead to ineffective treatment of Alzheimer's symptoms or potentially cause the drug to be released too quickly or too slowly.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.